-+ 0.00%
-+ 0.00%
-+ 0.00%

Qiagen publishes transcript of preliminary Q1 2026 results call

PUBT·04/30/2026 10:53:01
Listen to the news
Qiagen publishes transcript of preliminary Q1 2026 results call
  • Qiagen hosted preliminary Q1 2026 results call attended by CEO Thierry Bernard, CFO Roland Sackers, VP Investor Relations Daniel Wendorff.
  • Qiagen posted preliminary net sales of USD 492 million, up 2% reported, down 1% at constant exchange rates.
  • Adjusted diluted EPS came in at USD 0.54 at constant exchange rates, matching outlook, while adjusted operating income margin was seen at about 27.4%.
  • Qiagen cut 2026 outlook to net sales growth of about 1%-2% at constant exchange rates, adjusted diluted EPS at least USD 2.43 at constant exchange rates.
  • Management attributed shortfall mainly to QuantiFERON immigration-testing demand reset, with QuantiFERON now seen steady at about USD 500 million in 2026 versus prior target about USD 535 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.